Fundraising Fox
/Companies
Sign in

Codexis

NASDAQ: CDXS

Redwood City, US · 4 known investors

Find your way into Codexis

Sign up to see every warm intro you have to Codexis

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Codexis team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Codexis provides enzyme engineering and biocatalysis services for RNA and small molecule API manufacturing, offering RNAi/siRNA and enzymatic synthesis solutions to pharmaceutical partners. It supports customers from process development through scalable commercial supply using an in-house pilot plant and CMO network.

Advanced ManufacturingAI & Machine LearningBiotechDeep Tech

Founders & leadership

GSGordon Sangster
Gordon SangsterCFO2014–2019
JNJohn Nicols
John NicolsPresident & CEO2012–2022John Nicols served as CEO of Codexis for a decade, leading enzyme engineering and biocatalysis services for pharmaceutical manufacturing. He previously spent 22 years as a senior executive at specialty chemicals company Albemarle Corp, and has served on corporate and nonprofit boards including Codexis, Antheia Inc., and Scientific Bioprocessing Inc.
DS
David SmithNamed on SEC filing

Board

TB
Thomas BaruchBoard director
PC
Pam ChengBoard director
KG
Kathleen GlaubBoard Director2014–2019Executive Officer, Director at Afferent Pharmaceuticals
BK
Bernard KelleyBoard director
BD
Byron DorganBoard director
PY
Patrick YangBoard director
DW
Dennis WolfBoard director

Investors · 4

FirstMark CapitalreportedNew York · $500K – $8M

How we know: the S-1 prospectus · Not right? Tell us

Also in the syndicate · 2

Cantor Fitzgerald & Co.Piper Sandler & Co.

Funding

SEC filings, press & company announcements

$50M disclosed across 1 of 3 rounds · 2019–2026

  • Undisclosed amountpublic offeringJul 2026

    Cantor Fitzgerald & Co., Piper Sandler & Co.

    Source ↗
▶$50MraisedJun 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gordon SangsterExecutive Officer
  • John NicolsExecutive Officer, Director
  • Pam ChengDirector
  • Kathleen GlaubDirector
  • Bernard KelleyDirector
  • Byron DorganDirector
  • Thomas BaruchDirector
  • Patrick YangDirector
  • Dennis WolfDirector
  • David SmithDirector
Offering amount
$50M
Amount sold
$50M
First sale
Jun 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$442.9Mvaluation at IPOApr 2010 · $13.00/share · 424B1
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

The Codexis mafia →

7 people who came through Codexis went on to found or lead other companies.

Ryan MartineauCorporate StrategyFounded Redaptive +1Gjalt HuismanSenior Vice President, Strategic Development; General Manager, BiotherapeuticsFounded Embold TherapeuticsFrances H. ArnoldAdvisorFounded ProviviEzhil SubbianScientist III & Technical LeadFounded STRING BIOSpiros KambourakisManager Panel DevelopmentFounded CellibreAlan ShawFounder, President & CEO, BoardFounded CalystaGuillaume CottarelDirector/Associate Director, Cellular EngineeringFounded Aperiam Bio

Related companies · 2

ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
LeadIQLeadIQ offers a company search tool that provides B2B company profiles with data such as revenue, employee count, funding, and contact information to help sales teams find decision makers and build pipeline.

Companies working in the same space as Codexis.

In the news

Codexis posts higher 2026 revenue but stays in loss | CDXS Quarterly Report (10-Q)stocktitan.net · Aug 2026Codexis prices stock offering, raises $23.1M | CDXS 8-K Filingstocktitan.net · Jul 2026

Frequently asked questions

What does Codexis do?
Codexis provides enzyme engineering and biocatalysis services for RNA and small molecule API manufacturing, offering RNAi/siRNA and enzymatic synthesis solutions to pharmaceutical partners. It supports customers from process development through scalable commercial supply using an in-house pilot plant and CMO network.
Who are Codexis's investors?
Codexis's investors include Baruch Future Ventures, FirstMark Capital.
How much funding has Codexis raised?
Codexis has disclosed $50M raised across 1 of its 3 known rounds.
Where is Codexis headquartered?
Codexis is headquartered in Redwood City, US.